Sygnature Discovery a leading independent integrated drug discovery and pre-clinical services company, is continuing the expansion of its operations with the opening of its first US office, located in Harvard Square, Cambridge, Massachusetts.
Since its inception in 2004, Sygnature has worked closely with a range of pharmaceutical and biotech clients across the USA to conduct high quality research towards developing new and innovative medicines. To foster an even stronger commitment to the US market and to its US clients, earlier in 2018, Sygnature appointed its first US based business development representative to build on its long-standing North American presence. The USA is Sygnature Discovery’s largest market and with the new office location the company is further strengthening its commitment to better serving its US customer base.
Commenting on the expansion, Sygnature Discovery’s CEO Dr Simon Hirst said: “Clients from all over the world come to Sygnature because we are able to offer not only a high-quality, fully-integrated drug discovery and pre-clinical service, but we also have the flexibility to provide stand-alone medicinal chemistry, in vitro biology, computational chemistry, DMPK and pre-clinical experimental services through our subsidiary company, RenaSci. As a business we have seen significant growth outside of the UK in recent years; particularly in the USA. The Boston and Cambridge area is a key life sciences hub and our office location there will ensure that we are closer to many of our key customers, both current and potential.”
The Harvard Square office is the second location Sygnature adds this year, following the news in August 2018 announcing their new DMPK facility in Alderley Park in Cheshire, UK.
For further information, visit: www.sygnaturediscovery.com
About Sygnature Discovery
Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services company. Private equity-backed, we operate fully-enabled research facilities in Nottingham and Alderley Park, UK, housing over 200 research scientists (80% with PhDs). Our experienced drug hunters possess all of the professional skills and know-how required to undertake the most demanding of research programmes and drive them from target validation, through hit identification, hit-to-lead and lead optimisation to pre-clinical development candidate. Since 2011, we have delivered 14 drug candidates to our clients which have subsequently entered the clinic (Phases I and II). In 2017, Sygnature Discovery received the prestigious Queen’s Award for Enterprise for International Trade.
